A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

The goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent clinical relapse. Participants will undergo MRD surveillance and be subjected to intervention in case of MRD positivity. Results will be compared with NMDSG14B, part one, in which MRD was analyzed in included patients without recieving intervention.

Trial Details

NCT ID
NCT05788679
Phase
PHASE2
Sponsor
Karolinska University Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Donor lymphocytes
  • Tapering of immune suppression
Locations (sample)
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Signed informed consent
  • Age ≥ 18 years
  • Subjects eligible for SCT
  • Subjects having the disease MDS, mixed myelodysplastic/myeloproliferative syndrome or AML with myelodysplasia related dysplasia and 20-29% marrow b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →